MEDSIR, a global leader in oncology research, today presented significant breakthroughs in the fight against aggressive breast cancer at the 46th San Antonio Breast Cancer Symposium (SABCS) that have the potential to transform the lives of breast cancer patients.
Amgen (NASDAQ:AMGN) today announced the presentation of new data from its blood cancer portfolio and pipeline at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place from Dec. 9-12 in San Diego.
AMGEN HIGHLIGHTS HEMATOLOGY PORTFOLIO AT ASH 2023 Read More »
Intensity Therapeutics, Inc. today announced that safety, tolerability, efficacy and immune activation data from the company’s Phase 2 INVINCIBLE trial of INT230-6 in patients with early-stage breast cancer without chemotherapy was presented at a Podium Poster Spotlight discussion session today during the 2023 San Antonio Breast Cancer Symposium (SABCS). Information on the presentation is below.
Novartis today announced results from an updated invasive disease-free survival (iDFS) analysis of the pivotal Phase III NATALEE trial, with a median follow-up of 33.3 months and following Kisqali® (ribociclib) treatment completion by 78.3% of patients.
Alveolus Bio today announced a strategic scientific collaboration with BiomEdit, an emerging animal health biotechnology company leveraging microbiome science and synthetic biology to develop novel products to prevent and treat disease in animals.
Alveolus Bio Enters Into Strategic Collaboration with BiomEdit Read More »
For the second time in as many days, Merck has reported a Phase III failure for its blockbuster PD-1 inhibitor Keytruda, this time as a first-line treatment with Eisai’s Lenvima for cancer in the uterus lining.
Merck’s Keytruda Flops in Late-Stage Endometrial Carcinoma Study Read More »
Results from a Phase III trial showed the combination improves progression-free survival compared to chemotherapy when used as a first-line treatment in metastatic colorectal cancer.
BMS Builds Case for Opdivo, Yervoy Combo in First-Line Colorectal Cancer Read More »
The biopharma industry is projected to raise $24 billion this year, a steep decline from the “high-water marks” of 2020 through 2022, according to a new report from market data firm PitchBook.
Biopharma Funding, Deals Fall Sharply in 2023 in ‘Strategic’ Shift: PitchBook Read More »
FluoGuide A/S, a pioneer in the cutting-edge field of precision cancer surgery, announced the status of the exercised warrants, issued in connection with the directed share issue in July this year, raising SEK 12 million.
FluoGuide Raises SEK 12 million through Exercise of Warrants Read More »
TILT Biotherapeutics presented safety and efficacy data from its international Phase I trial in patients with metastatic melanoma, in an oral presentation at the ESMO Immuno-Oncology Congress in Geneva, Switzerland.
